Is brigatinib included in medical insurance?

Brigatinib (Brigatinib) is a new type of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor, mainly used to treat ALK-positive non-small cell lung cancer (NSCLC). This drug is manufactured byAriad Developed by PharmaceuticalsCompany, it was first approved by the U.S. Food and Drug Administration (FDA) in 2017 for Treatment of ALKpositiveNSCLC patients who have developed resistance to crizotinib (Crizotinib) therapy.

Brigatinib is now available in China and included in the medical insurance catalog. Patients can purchase it domestically at a price of about four to five thousand yuan. For specific prices and medical insurance reimbursement policies, please consult your local hospital pharmacy for detailed information. Compared with domestic prices, the prices of generic drugs in foreign markets are relatively low, especially those in Laos. The price is about a few hundred yuan, which is far lower than the domestic price, and its drug ingredients are basically the same as the original drugs.

Brigatinib (Brigatinib) As a second-generationALK inhibitor, it is designed to solve the drug resistance problem encountered in clinical treatment with first-generation drugs (such as crizotinib). Compared with crizotinib, Brigatinib (Brigatinib) has higher selectivity and stronger inhibitory ability, and can effectively combat a variety of ALK mutants, including crizotinib-resistant mutants such as L1196M pan>, G1269A, S1206Y and F1174C etc. In addition, Brigatinib also has the ability to penetrate the blood-brain barrier and has a good effect on brain metastasis, which is of great significance in the treatment of patients with advanced NSCLC.

Clinical trial data for brigatinib support its significant efficacy in the treatment of ALKpositive NSCLC. In a product calledALTA-1LIn the III clinical trial, brigatinib (brigatinib) significantly prolonged the progression-free survival of patients compared with crizotinib ( pan>PFS), and showed clear advantages in terms of overall survival (OS) and objective response rate (ORR). These results show that brigatinib (brigatinib) performs well not only in patients who are resistant to crizotinib but also in patients who have not receivedALK inhibitor treatment.

Common side effects of brigatinib include nausea, diarrhea, headache, cough and fatigue, and most side effects are mild and controllable. However, Brigatinib may also cause serious adverse reactions, such as interstitial lung disease, hypertension, and hyperglycemia, so patients need to be closely monitored during use.